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ABSTRACT
Introduction: Mutations (MT) of the KRAS gene are the most common mutation 
in non-small cell lung cancer (NSCLC), seen in about 20–25% of all adenocarcinomas. 
Effect of KRAS MT on response to cytotoxic chemotherapy is unclear.
Methods: We undertook a single-institution retrospective analysis of 93 
consecutive patients with stage IV NSCLC adenocarcinoma with known KRAS and EGFR 
MT status to determine the association of KRAS MT with survival. All patients were 
treated between January 1, 2008 and December 31, 2011 with standard platinum based 
chemotherapy at the University of Pennsylvania. Overall and progression free survival 
were analyzed using Kaplan-Meier and Cox proportional hazard methods. 
Results: All patients in this series received platinum doublet chemotherapy, and 
42 (45%) received bevacizumab. Overall survival and progression free survival for 
patients with KRAS MT was no worse than for patients with wild type KRAS. Median 
overall survival for patients with KRAS MT was 19 months (mo) vs. 15.6 mo for KRAS 
WT, p = 0.34, and progression-free survival was 6.2 mo in patients with KRAS MT 
vs. 7mo in patients with KRAS WT, p = 0.51. In multivariable analysis including age, 
race, gender, and ECOG PS, KRAS MT was not associated with overall survival (HR 
1.12, 95% CI 0.58–2.16, p = 0.74) or progression free survival (HR 0.80, 95% CI 
0.48–1.34, p = 41). Of note, receipt of bevacizumab was associated with improved 
overall survival only in KRAS WT patients (HR 0.34, p = 0.01).
Conclusions: KRAS MT are not associated with inferior progression-free and 
overall survival in advanced NSCLC patients treated with standard first-line platinum-
based chemotherapy.
INTRODUCTION
Our understanding of the biology of NSCLC 
has accelerated dramatically with the recognition that 
oncogenic driver mutations often play a decisive role 
in prognosis and treatment response. The introduction 
of molecular markers is transforming the treatment 
paradigms for this disease [1–4]. One of the most 
common molecular changes in NSCLC is mutations 
in KRAS, usually point mutations in codon 12 or 13. 
KRAS is a member of the RAS family of oncogenes 
that encode small GTPases involved in cellular signal 
transduction. KRAS mutations (MT) are more common 
in adenocarcinoma than in other NSCLC histologies [5]. 
KRAS MT occur more often in smokers than nonsmokers 
[6–9] unlike EGFR mutations and ALK translocations. 
Targeted therapies, including tyrosine kinase inhibitors 
(TKIs), for EGFR and EML-4ALK mutations have 
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improved progression-free survival in patients bearing 
the relevant mutations [1–3]. Despite initial forays [10] 
into targeted therapy for KRAS MT NSCLC, there are no 
such approved agents at this time.
Much of the existing literature suggests that NSCLC 
patients with KRAS MT have inferior outcomes compared 
to those with KRAS WT [7, 11–13]. This literature has 
a number of serious limitations, however, including 
small sample sizes and patient heterogeneity. A number 
of studies have analyzed patient series comprising 
a mix of patients with different NSCLC histologies 
(adenocarcinoma and squamous cell carcinoma) and 
stages [7, 11, 13–18].
The predictive value of KRAS mutations in 
NSCLC for therapy selection also remains unclear [19, 
20]. Various reports have suggested that treatment with 
TKIs such as erlotinib results in inferior outcomes in 
patients with KRAS MT NSCLC, [12, 21] but this view 
is not universal [22]. While KRAS MT status is clearly 
associated with lack of response to the anti-EGFR 
antibody cetuximab in colorectal cancer, [23] in lung 
adenocarcinoma KRAS MT status does not appear to 
predict response to this agent [24].
Similarly, there are reports suggesting an adverse 
effect of chemotherapy in patients with KRAS MT 
compared to KRAS WT [20]. For the most part the series 
are small and cover diverse therapeutic settings (adjuvant 
therapy [14] and therapy of stage IV disease) and some of 
the older studies used older chemotherapy regimens such 
as cisplatin and vinorelbine.
In the absence of targeted therapies, and personalized 
approaches, platinum doublet chemotherapy (with or 
without bevacizumab) remains the current standard of 
care for these patients. Given persistent uncertainty about 
the predictive value of KRAS MT status in NSCLC, 
we performed a retrospective, single-institution study 
to determine the relationship between KRAS MT and 
survival after platinum-based chemotherapy in patients 
with stage IV lung adenocarcinoma.
RESULTS
Study population and frequency of KRAS 
mutations
Median age was 60 years; 51% were women and 
20% were lifelong nonsmokers. Baseline characteristics 
were similar in both groups (Table 1). Thirty-eight (40%) 
patients had KRAS MT (See Table 2). Of the 55 KRAS 
wild type (WT) subjects, 5 (5%) had EGFR MT, and 
50 (53%) were EGFR WT. Most patients had an ECOG 
performance status of 0 or 1 (34% and 49%, respectively). 
The majority of KRAS MT were codon 12 mutations with 
2 codon 13 mutations and 1 not specified. Gly12Cys was 
the most common amino acid substitution (15 patients), 
followed by Gly12Val (11 patients). KRAS MTs were 
more common in current or previous smokers compared 
to lifelong nonsmokers (47% vs 16% p = 0.01).
Treatment
All subjects received first-line platinum doublet 
chemotherapy; 96% received carboplatin and the remainder 
cisplatin. A majority of patients (78%) received pemetrexed 
as the platinum partner; 15 patients (16%) received either 
paclitaxel or docetaxel (Table 1). Nearly half (45%) the 
subjects received bevacizumab in addition to the platinum 
doublet. Patients with KRAS MT were as likely as patients 
without KRAS MT to receive pemetrexed or bevacizumab 
based chemotherapies (Table 1).
Effect of KRAS on overall survival and 
progression-free survival
Among 47 patients who were still alive at the close 
of the study, median length of follow-up was 30 months 
(range 2–51 months). There were 46 (49%) deaths during 
the study period, with a median OS for all patients of 
19.0 months (95%CI, 14.–28.9 months). There was no 
significant difference in OS between patients with KRAS 
WT and KRAS MT (median OS 19 months vs. 15.6 
months, p = 0.34; Figure 1A). There were a total of 81 
(90%) patients with progression during the study period, 
with a median PFS for all subjects of 6.9 months (95%CI, 
4.9 to 9.3 months). There was no significant difference 
in PFS between patients with KRAS WT and KRAS MT 
(median PFS 6.2 mo vs. 7.0 mo; p = 0.51; Figure 1B).
Sex, age, and tobacco history were not associated 
with overall survival or PFS in univariate analyses 
(Table 3 for OS, data for PFS not shown). There was, 
however, significantly longer OS among patients with an 
ECOG performance status of 0 or 1 compared to patients 
with a performance status of 2 (median OS 28.9 months 
vs. 14.2 months; p = 0.01). In multivariable analysis 
controlling for age, race, gender, and ECOG PS, there 
was no significant difference in OS (HR 1.12, 95% CI 
0.58–2.16, p = 0.74) or PFS (HR 0.80, 95% CI 0.48–1.34, 
p = 41) between patients with KRAS MT and those with 
KRAS WT.
KRAS status and differential efficacy of 
bevacizumab
Nearly half (45%) of the subjects received 
bevacizumab. We evaluated the effect of bevacizumab 
therapy to determine whether outcomes varied by KRAS 
mutation status. Among KRAS WT patients, the use of 
bevacizumab in addition to platinum doublet therapy 
resulted in significant improvements in OS (median 28.9 
mo vs. 14.2 mo; p = 0.01) and PFS (median 9.5 mo vs. 4.8 
mo, p = 0.004). This effect remained significant for KRAS 
WT patients in multivariable analysis controlling for age, 
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race, gender, and ECOG PS (HR 0.34, 95% CI 0.13–0.94 
for OS and HR 0.37, 95% CI 0.19–0.72 for PFS), but was 
not seen in patients with KRAS MT (HR 0.88, 95%CI 
0.30–2.76 for OS and HR 0.96, 95% 0.35–2.62 for PFS).
DISCUSSION
We studied a consecutive series of patients with 
stage IV NSCLC adenocarcinoma and known EGFR and 
KRAS mutation status. In our population, KRAS MTs were 
common, similar to what has been observed in other series. 
As expected, KRAS MTs were more frequent in smokers 
and were nearly all codon 12 mutations. Our key finding 
is that KRAS MTs were not associated with OS or PFS 
when controlling for age, smoking status, and ECOG PS 
in a relatively uniform population of patients with stage IV 
adenocarcinoma receiving platinum doublet chemotherapy. 
In addition, we found that bevacizumab use was associated 
with significantly better outcome in the KRAS WT 
population, but not in those with KRAS MTs. A similar 
effect was observed in a study of neoadjuvant bevacizumab, 
where 10 patients with KRAS MT NSCLC who underwent 
resection did not have a major pathological response [27].
KRAS is the most frequently mutated oncogene in 
patients with lung adenocarcinoma, and many studies have 
been conducted to evaluate its clinical and therapeutic 
implications. Despite the successes with targeted therapy 
for driver mutations, personalized therapy for patients 
with KRAS MT is still under development. Platinum 
doublet chemotherapy, with or without bevacizumab, is 
the standard of care.
Table 1: Baseline characteristics of study population
KRAS WT (N = 55) KRAS MT (N = 38) p-value
Age, mean (SD) 58.0 (±11.6) 62.8 (±11.8) P = 0.06
Sex, n(%)
 Male
 Female
31 (56)
24 (43)
15 (39)
23 (61) p = 0.11
Race, n(%)
 White
 African-American
 Asian
45 (82)
8 (15)
2 (4)
34 (89)
4 (11)
0 (0)
p = 0.60
Smoking status, n(%)
 Never
 Former
 Current
16 (29)
27 (49)
12 (22)
3 (8)
23 (60)
12 (32)
p = 0.04
Pack-years, mean (SD) 37.0 (23.5) 34.0 (26.9) p = 0.62
ECOG performance status, n(%)
 0
 1
 2
18 (32)
30 (55)
7 (13)
15 (39)
15 (39)
8 (21)
p = 0.34
Platinum chemotherapy, n(%)
 Carboplatin
 Cisplatin
53 (96)
2 (4)
36 (95)
5 (5)
Pemetrexed, n(%) 42 (76) 31 (82) p = 0.55
Bevacizumab, n(%) 26 (47) 16 (42) p = 0.62
Table 2: KRAS and EGFR mutation status
N Percent
KRAS MT 38 41%
 Codon 12 35
 Codon 13 2
EGFR MT 5 5%
KRAS WT and EGFR WT 49 53%
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Figure 1A: Overall Survival. There was no significant difference in OS between patients with KRAS WT and KRAS MT (median OS 
19 months vs. 15.6 months, p = 0.34).
Figure 1B: Progression-free survival. There was no significant difference in PFS between patients with KRAS WT and KRAS MT 
(median PFS 6.2 mo vs. 7.0 mo; p = 0.51).
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The predictive role of KRAS is controversial, 
with prior studies of KRAS MT in lung adenocarcinoma 
yielding contradictory conclusions. In the adjuvant 
setting, the relationship of KRAS MT to chemotherapy 
was explored in a molecular analysis of the patients 
included in the JBR.10 clinical trial. In this analysis, 
KRAS MT were neither prognostic of survival nor 
predictive of a differential benefit from adjuvant cisplatin 
and vinorelbine [15]. Shepherd et al reached similar 
conclusions in their exploratory analyses characterizing 
relationships between KRAS MT and survival outcomes 
across three adjuvant trials from the LACE BIO meta-
analysis. They analyzed 300 patients with KRAS MT 
(predominantly codon 12 mutations). For the patients that 
received adjuvant chemotherapy, no significant benefit 
was observed for KRAS WT or patients with codon-12 
KRAS MT. However, for patients with codon 13 KRAS 
MT, adjuvant chemotherapy was associated with a worse 
survival. Since the number of patients with codon 13 MT 
was small, the authors concluded that KRAS status could 
not be recommended to select patients with NSCLC for 
adjuvant chemotherapy [14].
Furthermore, retrospective studies in the metastatic 
setting have shown mixed chemotherapy effect based on 
the presence or absence of a KRAS MT [28, 29]. Sun et 
al [20] reported a worse response rate and PFS for the 
pemetrexed-based regimen in KRAS MT compared to 
KRAS WT subjects; KRAS MT were also associated with 
inferior outcomes after gemcitabine-based chemotherapy, 
but there was no difference in KRAS MT and WT patients 
receiving a taxane-based regimen.
In contrast to the previous studies, we did not 
find a worse survival outcome for patients with KRAS 
MT. Majority of our patients had codon 12 MT, and 
were treated with a pemetrexed based regimen, making 
comparisons between different chemotherapy regimens 
difficult. Our study adds to the above literature by 
exploring the relationship of KRAS MT to survival in 
patients with metastatic adenocarcinoma. The strength 
of our investigation is our relatively homogenous pt 
population: all patients had stage IV adenocarcinoma, 
the percentage of KRAS MT is similar to that reported 
in the literature, all patients received platinum based 
doublet chemotherapy in 1st line and a majority of 
patients received a contemporary regimen of carboplatin 
and pemetrexed. In addition, a significant proportion of 
the patients received bevacizumab, making this the largest 
study to explore the relationship of bevacizumab and 
KRAS MT.
Our study also has several important limitations: 
first, it is a retrospective study, and inclusion was 
limited to patients that had been tested for EGFR and 
KRAS MT. Second, although our study population is 
large compared to most of the existing literature it is 
nevertheless relatively small. Third, progression events 
were determined based on the assessment of the treating 
oncologist abstracted from the medical record and not 
by the formal RECIST metrics that might be used in 
a clinical trial. Fourth, our analysis mainly describes 
the prognostic role of KRAS codon 12 mutations and 
provides no insight into the role of KRAS MT codon 
13 mutations. Finally, since our patients received a 
Table 3: Overall Survival
Unadjusted model Multivariable model
Demographic or Characteristic No. of Patients (n = 93) Median OS (95% CI) P value HR (95% CI) P value
Gender
 Male 46 16.4 (10.1–32.6) 0.25 Ref. -
 Female 47 19.0 (12.5–xx) 0.81 (0.42–1.55) 0.52
 Age 93 NA NA 1.02 (0.99–1.06) 0.12
Race
 White 79 18.5 (12.5–28.9) 0.83 Ref. -
 Black/Other 14 Not Reached 0.58 (0.21–1.61) 0.20
ECOG PS
 0 33 28.9 (18.5–xx) 0.0003 Ref. -
 1 45 19.0 (9.8–xx) 1.93 (0.94–3.93) 0.07
 2 15 6.4 (1.7–14.5) 4.64 (1.97–10.9) <0.0001
KRAS
 WT 55 19.0 (14.2–xx) 0.34 Ref.
 MT 38 15.6 (9.8–24.4) 1.12(0.58–2.16) 0.74
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nearly homogenous treatment regimen, we are unable to 
analyze the effects of different chemotherapy regimens 
on outcome in patients with KRAS MT compared to 
KRAS WT NSCLC. However, the high percentage of 
patients receiving pemetrexed in our study is a notable 
difference from prior studies [12, 20] which for the 
most part noted inferior survival for KRAS MT patients 
receiving systemic chemotherapy with pemetrexed [20]. 
Based on our observations, it is possible that pemetrexed 
may have a more favorable effect on KRAS MT tumors 
than, but our study was not designed to answer this 
question in a formal manner.
Our study suggests that KRAS MT is not 
associated with worse PFS and OS in advanced NSCLC 
patients treated with platinum doublet chemotherapy. 
Our study suggests that patients with KRAS WT may 
benefit more from bevacizumab compared to patients 
with KRAS MT. Due to the small sample size of our 
patient population, this observation is purely hypothesis 
generating, and needs further analysis. Our results are 
not generalizable to earlier-stage or non-adenocarcinoma 
NSCLC. Based on our observations, patients with Stage 
IV KRAS MT NSCLC should be treated with similar 
chemotherapy regimens as KRAS WT patients, including 
the use of bevacizumab when clinically appropriate. 
Furthermore, the differential effects of codon 12 and 
codon 13 KRAS MT should also be analyzed in a larger 
population; utilizing next generation sequencing in 
the future would be helpful to explore relationship of 
different genetic subgroups to overall outcome. In the 
future, the real utility of KRAS testing will depend on 
the availability of KRAS directed therapeutics, which 
has been elusive to date.
MATERIALS AND METHODS
Patient population
Consecutive patients diagnosed with Stage IV 
NSCLC seen at the University of Pennsylvania’s 
Abramson Cancer Center between January 1, 2008 
and December 31, 2011 were analyzed retrospectively. 
Patients with histology other than adenocarcinoma or 
adenosquamous cancer and patients with stages other 
than AJCC 7th edition [25] stage IV at presentation 
were excluded. Patients who did not receive treatment 
(i.e., were seen only once in consultation) were also 
excluded, as were those who received no chemotherapy 
(for example, radiation only) or who received first-line 
erlotinib. Only patients with known KRAS and EGFR 
MT status were included. Absence of known EML4-
ALK status was permitted given the era in which the 
study was conducted. Ninety-three patients were 
included in the final analysis. This study was approved 
by the Institutional Review Board of the University of 
Pennsylvania.
Mutational analysis
Patients were included only if a written report of 
the mutational analysis could be verified. EGFR and 
KRAS immunohistochemistry or amplification was not 
considered. Only EGFR mutations known to be correlated 
with prognosis (i.e., exon 19 deletion or exon 21 L858R) 
were considered in our analysis. All KRAS and EGFR 
mutation testing was done with quantitative polymerase 
chain reaction. Genomic DNA was extracted from tumor 
specimens. KRAS mutations in codons 12 and 13 were 
assessed by direct sequencing of exon 2 using primers for 
the seven most common point mutations (nucleotides c.34G, 
c.35G and c.38G) (NM_004985.3). EGFR mutations were 
assessed by polymerase chain reaction (PCR)-based methods 
that detect exon 19 deletions and exon 21 leucine-to-arginine 
codon 858 (L858R) amino acid substitutions [26].
Clinical data
The following information was collected from the 
electronic medical record: age at diagnosis, sex, race, 
ethnicity, smoking status, ECOG performance status at 
diagnosis; stage at diagnosis (TNM, according to AJCC 
7th edition guidelines), histology, method of diagnosis, 
date of diagnosis; treatment (first, second and third line 
therapies) and its outcome (response, progression, stable 
disease), EGFR and KRAS mutation status and whether 
EML4-ALK mutation testing was performed.
Statistical analysis
Progression-free-survival (PFS) was calculated 
from date of diagnosis to date of death or progression; 
the date of progression was based on documentation 
by the treating oncologist in the electronic medical 
record. Overall survival (OS) was calculated from date 
of diagnosis to date of death or date of last follow-
up. Patients were censored at 5/31/2012 or last follow 
up visit if they were subsequently lost to follow-up 
prior to the end of data collection. Chi-square analysis 
was used to describe the relationship of KRAS MT to 
smoking status (never vs. current or former smoker). 
Kaplan-Meier analysis was used to estimate overall 
and progression-free survival. Cox proportional hazard 
models were used to determine the relationship of 
KRAS MT to survival, with adjustment for ECOG PS, 
gender, race, and age. To assess the proportional hazards 
assumption, we used the Schoenfeld residuals test and 
complementary log-log plots.
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